organization · Reporting owner
JOHNSON & JOHNSON
Disclosed activity across 23 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANIMAS CORPPUMP · Entity 13779 | 10% owner | December 16, 2005 | December 21, 2005 |
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | 10% owner | May 01, 2014 | May 05, 2014 |
| BARRIER THERAPEUTICS INCBTRX · Entity 13927 | 10% owner | February 15, 2005 | February 15, 2005 |
| CLOSURE MEDICAL CORPCLSR · Entity 13914 | 10% owner | March 03, 2005 | March 11, 2005 |
| CRITICAL THERAPEUTICS INCCRTX · Entity 14044 | 10% owner | June 02, 2004 | June 02, 2004 |
| CVRx, Inc.CVRX · Entity 6920 | 10% owner | November 25, 2025 | January 08, 2026 |
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | 10% owner | April 09, 2024 | April 10, 2024 |
| MeiraGTx Holdings plcMGTX · Entity 4734 | 10% owner | November 09, 2022 | November 14, 2022 |
| OPKO HEALTH, INC.EXEG · Entity 4891 | 10% owner | March 27, 2007 | April 06, 2007 |
| PROTEIN POLYMER TECHNOLOGIES INCPPTI.OB · Entity 14096 | 10% owner | December 31, 2003 | February 17, 2004 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | 10% owner | August 16, 2016 | August 18, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANIMAS CORP
Report date December 16, 2005 · Filed December 21, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | IndirectSee explanatory note (1) below | 6,153,393 |
Reported balance
Holding disclosure · report date 2005-12-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,153,393 F1: Johnson & Johnson, a New Jersey Corporation, is party to a Stockholder Agreement dated as of December 16, 2005 with certain stockholders of Animas Corporation (the ?Stockholder Agreement?). Pursuant to the Stockholder Agreement, Johnson & Johnson may be deemed a beneficial owner pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the ?Act?), of 6,153,393 shares of common stock, par value $0.01 per share, of Animas Corporation that are subject to the Stockholder Agreement (the ?Shares?). Pursuant to Rule 16a-1(a)(4) under the Act, Johnson & Johnson hereby states that this Initial Statement of Beneficial Ownership of Securities on Form 3 shall not be deemed an admission that Johnson & Johnson is, for purposes of Section 16 of the Act or otherwise, the beneficial owner of the shares. Johnson & Johnson has no pecuniary interest in the Shares. |
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | IndirectSee explanatory note (2) below. | 1,616,488 |
Reported balance
Holding disclosure · report date 2005-12-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,616,488 F2: As a result of a past acquisition of 1,616,488 shares of Animas Corporation common stock by Johnson & Johnson Development Corporation ("JJDC"), a wholly owned subsidiary of Johnson & Johnson, Johnson & Johnson may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The acquisition of these securities was reported on a Schedule 13G filed on February 3, 2005. |
Filing footnotes · ownership attribution and instrument terms
F1: Johnson & Johnson, a New Jersey Corporation, is party to a Stockholder Agreement dated as of December 16, 2005 with certain stockholders of Animas Corporation (the ?Stockholder Agreement?). Pursuant to the Stockholder Agreement, Johnson & Johnson may be deemed a beneficial owner pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the ?Act?), of 6,153,393 shares of common stock, par value $0.01 per share, of Animas Corporation that are subject to the Stockholder Agreement (the ?Shares?). Pursuant to Rule 16a-1(a)(4) under the Act, Johnson & Johnson hereby states that this Initial Statement of Beneficial Ownership of Securities on Form 3 shall not be deemed an admission that Johnson & Johnson is, for purposes of Section 16 of the Act or otherwise, the beneficial owner of the shares. Johnson & Johnson has no pecuniary interest in the Shares.
F2: As a result of a past acquisition of 1,616,488 shares of Animas Corporation common stock by Johnson & Johnson Development Corporation ("JJDC"), a wholly owned subsidiary of Johnson & Johnson, Johnson & Johnson may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The acquisition of these securities was reported on a Schedule 13G filed on February 3, 2005.
Aldeyra Therapeutics, Inc.
Report date May 01, 2014 · Filed May 05, 2014
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohnson & Johnson Development Corporation | 1,750,292 |
Last balance in matching sequence
After 2014-05-01 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2014-05-01 · Conversion · Acquired 1,724,478 · Balance 1,724,478 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2014-05-01 · Exercise / conversion · Acquired 36,345 · Balance 1,760,823 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 3 · 2014-05-01 · Tax withholding · Disposed 23,438 · Balance 1,737,385 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 4 · 2014-05-01 · Exercise / conversion · Acquired 36,345 · Balance 1,773,730 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 5 · 2014-05-01 · Tax withholding · Disposed 23,438 · Balance 1,750,292 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2014-05-01 · Conversion · Disposed 385,800 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Non-Voting Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2014-05-01 · Conversion · Disposed 104,396 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2014-05-01 · Conversion · Disposed 427,591 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Non-Voting Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2014-05-01 · Conversion · Disposed 133,827 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2017-12-20 | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2014-05-01 · Exercise / conversion · Disposed 36,345 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2018-08-14 | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2014-05-01 · Exercise / conversion · Disposed 36,345 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis.
F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis.
BARRIER THERAPEUTICS INC
Report date February 15, 2005 · Filed February 15, 2005
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc., Johnson & Johnson Consumer Companies, Inc., Janssen Pharmaceutica Products, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy three subsidiaries | 3,753,749 |
Reported balance
After 2005-02-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2005-02-15 · Sale · Disposed 694,327 · Balance 3,753,749 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person: Johnson & Johnson Development Corporation ("JJDC") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. ("JJCC") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. ("JPP") (selling 508,689 shares of Common Stock). Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person: Johnson & Johnson Development Corporation ("JJDC") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. ("JJCC") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. ("JPP") (selling 508,689 shares of Common Stock). Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock.
CLOSURE MEDICAL CORP
Report date March 03, 2005 · Filed March 11, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | IndirectSee explanatory note below. | 5,055,948 |
Reported balance
Holding disclosure · report date 2005-03-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,055,948 F1: Johnson & Johnson, a New Jersey Corporation, is party to a Stockholder Agreement dated as of March 3, 2005 with certain stockholders of Closure Medical Corporation (the "Stockholder Agreement). Pursuant to the Stockholder Agreement, Johnson & Johnson may be deemed a beneficial owner pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), of 5,055,948 shares of common stock, par value $0.01 per share, of Closure Medical Corporation that are subject to the Stockholder Agreement (the "Shares"). Pursuant to Rule 16a-1(a)(4) under the Act, Johnson & Johnson hereby states that this Initial Statement of Beneficial Ownership of Securities on Form 3 shall not be deemed an admission that Johnson & Johnson is, for purposes of Section 16 of the Act or otherwise, the beneficial owner of any equity securities of Closure Medical Corporation. Johnson & Johnson has no pecuniary interest in the Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Johnson & Johnson, a New Jersey Corporation, is party to a Stockholder Agreement dated as of March 3, 2005 with certain stockholders of Closure Medical Corporation (the "Stockholder Agreement). Pursuant to the Stockholder Agreement, Johnson & Johnson may be deemed a beneficial owner pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), of 5,055,948 shares of common stock, par value $0.01 per share, of Closure Medical Corporation that are subject to the Stockholder Agreement (the "Shares"). Pursuant to Rule 16a-1(a)(4) under the Act, Johnson & Johnson hereby states that this Initial Statement of Beneficial Ownership of Securities on Form 3 shall not be deemed an admission that Johnson & Johnson is, for purposes of Section 16 of the Act or otherwise, the beneficial owner of any equity securities of Closure Medical Corporation. Johnson & Johnson has no pecuniary interest in the Shares.
CRITICAL THERAPEUTICS INC
Report date June 02, 2004 · Filed June 02, 2004
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Development Corporation | 2,104,704 |
Last balance in matching sequence
After 2004-06-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2004-06-02 · Conversion · Acquired 1,961,904 · Balance 1,961,904 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. Row 2 · 2004-06-02 · Purchase · Acquired 142,800 · Balance 2,104,704 F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2004-06-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2004-06-02 · Conversion · Disposed 2,000,000 · Balance 0 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2004-06-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2004-06-02 · Conversion · Disposed 5,357,143 · Balance 0 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering.
F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.
CVRx, Inc.
Report date November 25, 2025 · Filed January 08, 2026 · Amendment
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 4,024,861 |
Last balance in matching sequence
After 2025-11-26 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-11-25 · Sale · Disposed 16,000 · Balance 4,031,198 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Row 2 · 2025-11-26 · Sale · Disposed 6,337 · Balance 4,024,861 F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Contineum Therapeutics, Inc.
Report date April 09, 2024 · Filed April 10, 2024
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,979,173 |
Reported balance
Holding disclosure · report date 2024-04-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,979,173 F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson.
MeiraGTx Holdings plc
Report date November 09, 2022 · Filed November 14, 2022
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 6,641,064 |
Reported balance
Holding disclosure · report date 2022-11-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,641,064 F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson.
OPKO HEALTH, INC.
Report date March 27, 2007 · Filed April 06, 2007
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series C Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F2: There is no expiration date applicable to the Series C Preferred Stock. F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2014-09-24 | IndirectBy Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2015-07-01 | IndirectBy Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2017-03-27 | IndirectBy Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2017-03-27 | IndirectBy Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2017-03-27 | IndirectBy Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2007-09-27 | Indirectby Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2007-09-27 | Indirectby Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2007-09-27 | Indirectby Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2007-09-27 | Indirectby Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F3: As of 3/27/07 vested as to 2,810 shares. F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2007-09-27 | Indirectby Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
Holding disclosure · report date 2007-03-27 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F4: As of 3/27/07 vested as to 56,218 shares. F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.
F2: There is no expiration date applicable to the Series C Preferred Stock.
F3: As of 3/27/07 vested as to 2,810 shares.
F4: As of 3/27/07 vested as to 56,218 shares.
PROTEIN POLYMER TECHNOLOGIES INC
Report date December 31, 2003 · Filed February 17, 2004
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series I Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.55 | IndirectBy Johnson & Johnson Development Corporation | 10,000 |
Reported balance
After 2003-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2003-03-10 · Purchase · Acquired 10,000 · Balance 10,000 F1: There is no expiration date applicable to the Series I Preferred Stock. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Series I First Common Stock Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2004-09-30 | IndirectBy Johnson & Johnson Development Corporation | 272,727 |
Reported balance
After 2003-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2003-03-10 · Purchase · Acquired 272,727 · Balance 272,727 F3: The warrants were issued in conjunction with the purchase of Series I Preferred Stock. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Series I Second Common Stock Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2007-03-31 | IndirectBy Johnson & Johnson Development Corporation | 181,818 |
Reported balance
After 2003-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2003-03-10 · Purchase · Acquired 181,818 · Balance 181,818 F3: The warrants were issued in conjunction with the purchase of Series I Preferred Stock. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: There is no expiration date applicable to the Series I Preferred Stock.
F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.
F3: The warrants were issued in conjunction with the purchase of Series I Preferred Stock.
Protagonist Therapeutics, Inc
Report date August 16, 2016 · Filed August 18, 2016
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 2,449,183 |
Last balance in matching sequence
After 2016-08-16 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2016-08-16 · Conversion · Acquired 965,517 · Balance 965,517 F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2016-08-16 · Conversion · Acquired 900,333 · Balance 1,865,850 F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 3 · 2016-08-16 · Purchase · Acquired 583,333 · Balance 2,449,183 F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2016-08-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-08-16 · Conversion · Disposed 14,000,000 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2016-08-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-08-16 · Conversion · Disposed 13,054,830 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date.
F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration.
F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Past disclosures · reporting ended (12)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date November 20, 2017 · Filed November 22, 2017
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2017-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2017-11-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-11-20 · Sale · Disposed 18,367,346 · Balance 0 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Fusion Pharmaceuticals Inc.
Report date June 30, 2020 · Filed July 02, 2020
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 3,670,516 |
Last balance in matching sequence
After 2020-06-30 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-30 · Conversion · Acquired 2,945,516 · Balance 2,945,516 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2020-06-30 · Purchase · Acquired 725,000 · Balance 3,670,516 F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Class A Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2020-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-30 · Conversion · Disposed 10,666,667 · Balance 0 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Class B Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2020-06-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-30 · Conversion · Disposed 5,059,460 · Balance 0 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Warrants to purchase Class B Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2020-06-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-30 · Conversion · Disposed 475,802 · Balance 0 F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Warrants to purchase Common SharesSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 89,118 |
Reported balance
After 2020-06-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-06-30 · Conversion · Acquired 89,118 · Balance 89,118 F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date.
F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share.
GENOCEA BIOSCIENCES, INC.
Report date February 10, 2014 · Filed February 11, 2014
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2014-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohnson & Johnson Development Corporation | 1,388,645 |
Reported balance
After 2014-02-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2014-02-10 · Conversion · Acquired 1,388,645 · Balance 1,388,645 F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2014-02-10 · Conversion · Disposed 827,917 · Balance 0 F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
After 2014-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2014-02-10 · Conversion · Disposed 351,866 · Balance Not disclosed F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock.
IMMUNICON CORP
Report date June 10, 2004 · Filed June 14, 2004
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2004-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Development Corporation | 1,771,571 |
Reported balance
After 2004-06-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2004-06-10 · Other · Acquired 2,667 · Balance 1,771,571 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person. |
| Common Stock Warrant PurchaseSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2004-07-14 | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2004-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2004-06-10 · Other · Disposed 2,667 · Balance 0 F2: Pursuant to the terms of the warrant, the Reporting Persons had 90 days from the date JJDC's director designee resigned from the Issuer's Board of Directors to exercise the warrant as no other director designee was selected by JJDC. JJDC's director designee resigned from the board on April 15, 2004, triggering the 90 day period. F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person.
F2: Pursuant to the terms of the warrant, the Reporting Persons had 90 days from the date JJDC's director designee resigned from the Issuer's Board of Directors to exercise the warrant as no other director designee was selected by JJDC. JJDC's director designee resigned from the board on April 15, 2004, triggering the 90 day period.
Inspire Medical Systems, Inc.
Report date May 07, 2018 · Filed May 07, 2018
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2018-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 235,251 |
Last balance in matching sequence
After 2018-05-07 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-05-07 · Conversion · Acquired 197,863 · Balance 197,863 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2018-05-07 · Conversion · Acquired 37,388 · Balance 235,251 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series E Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2018-05-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-07 · Conversion · Disposed 1,145,038 · Balance 0 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series F Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2018-05-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-07 · Conversion · Disposed 248,631 · Balance 0 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering.
F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate.
F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate.
F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Kenvue Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 182,329,550 |
Reported balance
After 2023-08-23 transaction · row 1
1 source rowRow 1 · 2023-08-23 · Other · Disposed 1,533,830,450 · Balance 182,329,550 F1: Johnson & Johnson disposed of 1,533,830,450 shares of Issuer common stock in exchange for 190,955,436 shares of Johnson & Johnson common stock pursuant to a registered exchange offer to holders of shares of Johnson & Johnson common stock. The final exchange ratio was 8.0324 shares of Issuer common stock per share of Johnson & Johnson common stock accepted in the exchange offer. |
Filing footnotes · ownership attribution and instrument terms
F1: Johnson & Johnson disposed of 1,533,830,450 shares of Issuer common stock in exchange for 190,955,436 shares of Johnson & Johnson common stock pursuant to a registered exchange offer to holders of shares of Johnson & Johnson common stock. The final exchange ratio was 8.0324 shares of Issuer common stock per share of Johnson & Johnson common stock accepted in the exchange offer.
Minerva Neurosciences, Inc.
Report date August 29, 2017 · Filed September 14, 2017
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2017-09-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2017-08-29 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-08-29 · Other · Disposed 3,892,256 · Balance 0 F1: The shares were repurchased by the Issuer at their par value in connection with the amendment of a co-development and license agreement between the Issuer and an affiliate of Johnson & Johnson Innovation - JJDC, Inc. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were repurchased by the Issuer at their par value in connection with the amendment of a co-development and license agreement between the Issuer and an affiliate of Johnson & Johnson Innovation - JJDC, Inc.
F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the Reporting Person.
NEVRO CORP
Report date December 31, 2015 · Filed February 12, 2016
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2016-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 2,066,740 |
Reported balance
After 2015-06-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2015-06-08 · Sale · Disposed 1,010,265 · Balance 2,066,740 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owed subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owed subsidiary of the Reporting Person.
Neurogene Inc.
Report date August 10, 2015 · Filed August 12, 2015
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2015-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohnson & Johnson Innovation - JJDC, Inc. | 100,000 |
Last balance in matching sequence
After 2015-08-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2015-08-10 · Sale · Disposed 231,455 · Balance 1,383,366 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014. Row 2 · 2015-08-11 · Sale · Disposed 1,283,366 · Balance 100,000 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.55 to $30.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.55 to $30.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Provention Bio, Inc.
Report date July 19, 2018 · Filed July 20, 2018
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2018-07-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 2,400,000 |
Reported balance
After 2018-07-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-07-19 · Conversion · Acquired 2,400,000 · Balance 2,400,000 F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2018-07-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-19 · Conversion · Disposed 2,400,000 · Balance 0 F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering.
F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
TENGION INC
Report date April 14, 2010 · Filed April 14, 2010
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2010-04-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohnson & Johnson Development Corporation | 1,194,654 |
Last balance in matching sequence
After 2010-04-14 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2010-04-14 · Conversion · Acquired 755,053 · Balance 794,654 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2010-04-14 · Purchase · Acquired 400,000 · Balance 1,194,654 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2010-04-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2010-04-14 · Conversion · Disposed 4,961,653 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2010-04-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2010-04-14 · Conversion · Disposed 2,162,818 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2010-04-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2010-04-14 · Conversion · Disposed 3,823,817 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration.
UNIVERSAL BIOSENSORS INC
Report date December 31, 2011 · Filed January 24, 2012
Jointly reported with Johnson & Johnson Innovation - JJDC, Inc.
Section 16 reporting ended · disclosed 2012-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Development Corporation | 15,749,937 |
Last balance in matching sequence
After 2011-09-08 transaction · row 17
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
17 source rowsRow 1 · 2011-03-08 · Sale · Disposed 25,000 · Balance 17,406,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 2 · 2011-03-09 · Sale · Disposed 25,000 · Balance 17,381,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 3 · 2011-03-10 · Sale · Disposed 25,000 · Balance 17,356,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 4 · 2011-03-21 · Sale · Disposed 4,900 · Balance 17,351,717 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 5 · 2011-03-29 · Sale · Disposed 32 · Balance 17,351,685 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 6 · 2011-03-30 · Sale · Disposed 155 · Balance 17,351,530 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 7 · 2011-04-14 · Sale · Disposed 10,000 · Balance 17,341,530 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 8 · 2011-04-15 · Sale · Disposed 7,500 · Balance 17,334,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 9 · 2011-04-18 · Sale · Disposed 8,000 · Balance 17,326,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 10 · 2011-04-20 · Sale · Disposed 10,000 · Balance 17,316,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 11 · 2011-04-21 · Sale · Disposed 35,000 · Balance 17,281,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 12 · 2011-04-27 · Sale · Disposed 10,000 · Balance 17,271,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 13 · 2011-04-28 · Sale · Disposed 10,000 · Balance 17,261,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 14 · 2011-04-29 · Sale · Disposed 10,000 · Balance 17,251,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 15 · 2011-07-28 · Sale · Disposed 341 · Balance 17,250,689 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 16 · 2011-08-01 · Sale · Disposed 752 · Balance 17,249,937 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 17 · 2011-09-08 · Sale · Disposed 1,500,000 · Balance 15,749,937 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2020 Filed Jul 2, 2020 20:58 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | ConversionClass A Preferred Shares · Derivative | 10,666,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000426 · edgar.xml · derivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Shares · 1,997,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F1 · derivative.exercise_date: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F1 · derivative.expiration_date: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:58 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | PurchaseCommon Shares | 725,000 | $17.00 | $12,325,000.00 |
DisclosureSEC source: 0000904454-20-000426 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 3,670,516 F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:58 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | ConversionCommon Shares | 2,945,516 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-20-000426 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 2,945,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 14:11 UTC | Provention Bio, Inc. PRVB · Entity 12101 | ConversionSeries A Preferred Stock · Derivative | 2,400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000479 · edgar.xml · derivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 2,400,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 14:11 UTC | Provention Bio, Inc. PRVB · Entity 12101 | ConversionCommon Stock | 2,400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-18-000479 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 2,400,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:50 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries F Preferred Stock · Derivative | 248,631 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000335 · edgar.xml · derivative · entry 4 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 37,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.exercise_price: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F1 · derivative.exercise_date: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.underlying_shares: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:50 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries E Preferred Stock · Derivative | 1,145,038 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000335 · edgar.xml · derivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 197,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.exercise_price: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F1 · derivative.exercise_date: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.underlying_shares: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:50 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 37,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-18-000335 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 235,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3 · price: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:50 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 197,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-18-000335 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 197,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2 · price: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 16:44 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | SaleCommon Stock | 18,367,346 | $2.75 | $50,510,201.50 |
DisclosureSEC source: 0000904454-17-000692 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| August 29, 2017 Filed Sep 14, 2017 20:33 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | OtherCommon Stock | 3,892,256 | $0.00 | $389.23 |
DisclosureSEC source: 0000904454-17-000612 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 F1 · kind: The shares were repurchased by the Issuer at their par value in connection with the amendment of a co-development and license agreement between the Issuer and an affiliate of Johnson & Johnson Innovation - JJDC, Inc. F1 · price: The shares were repurchased by the Issuer at their par value in connection with the amendment of a co-development and license agreement between the Issuer and an affiliate of Johnson & Johnson Innovation - JJDC, Inc. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the Reporting Person. Read SEC document |
| August 16, 2016 Filed Aug 18, 2016 21:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | ConversionSeries C Preferred Stock · Derivative | 13,054,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-16-001373 · edgar.xml · derivative · entry 5 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 900,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.underlying_shares: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F3 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| August 16, 2016 Filed Aug 18, 2016 21:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | ConversionSeries B Preferred Stock · Derivative | 14,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-16-001373 · edgar.xml · derivative · entry 4 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 965,517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.underlying_shares: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F3 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| August 16, 2016 Filed Aug 18, 2016 21:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | PurchaseCommon Stock | 583,333 | $12.00 | $6,999,996.00 |
DisclosureSEC source: 0000904454-16-001373 · edgar.xml · nonDerivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 2,449,183 F3 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| August 16, 2016 Filed Aug 18, 2016 21:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | ConversionCommon Stock | 900,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-16-001373 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 1,865,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F1 · price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| August 16, 2016 Filed Aug 18, 2016 21:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | ConversionCommon Stock | 965,517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-16-001373 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 965,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F1 · price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| August 11, 2015 Filed Aug 12, 2015 16:24 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 1,283,366 | $20.74 | $26,617,010.84 |
DisclosureSEC source: 0000904454-15-000512 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 100,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.55 to $30.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014. Read SEC document |
| August 10, 2015 Filed Aug 12, 2015 16:24 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 231,455 | $31.66 | $7,327,865.30 |
DisclosureSEC source: 0000904454-15-000512 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 1,383,366 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014. Read SEC document |
| June 08, 2015 Filed Jun 8, 2015 20:40 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 1,010,265 | $47.94 | $48,432,104.10 |
DisclosureSEC source: 0001144204-15-036056 · v412478_4.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 2,066,740 F1 · price: Represents the public offering price of $51.00 per share, less the underwriter's discount of $3.06 per share. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person (formerly known as Johnson & Johnson Development Corporation). Read SEC document |
| June 08, 2015 Filed Feb 12, 2016 16:48 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 1,010,265 | $48.00 | $48,492,720.00 |
DisclosureSEC source: 0000904454-16-000985 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 2,066,740 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owed subsidiary of the Reporting Person. Read SEC document |
| March 18, 2015 Filed Feb 12, 2016 16:54 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 607,903 | $4.93 | $2,996,961.79 |
DisclosureSEC source: 0000904454-16-000987 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 3,892,256 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owed subsidiary of the Reporting Person. Read SEC document |
| March 13, 2015 Filed Mar 17, 2015 22:43 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseWarrants (right to buy) · Derivative | 607,903 | $0.13 Strike: $5.77 | $75,987.88 |
DisclosureSEC source: 0001144204-15-016825 · v404607_4.xml · derivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation- JJDC, Inc. Disclosed balance after: 607,903 Underlying: Common Stock · 607,903 shares Expires 2017-03-18 F1 · date: The transaction is subject to customary closing conditions and is expected to close on or about 03/18/2015. F1 · derivative.exercise_date: The transaction is subject to customary closing conditions and is expected to close on or about 03/18/2015. F3 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person (formerly known as Johnson & Johnson Development Corporation). Read SEC document |
| March 13, 2015 Filed Mar 17, 2015 22:43 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 607,903 | $4.81 | $2,924,013.43 |
DisclosureSEC source: 0001144204-15-016825 · v404607_4.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,500,159 F1 · date: The transaction is subject to customary closing conditions and is expected to close on or about 03/18/2015. F2 · balance_after: Consists of 3,892,256 shares of Common Stock and 607,903 shares of Common Stock underlying immediately exercisable warrants. F3 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person (formerly known as Johnson & Johnson Development Corporation). Read SEC document |
| December 17, 2014 Filed Dec 18, 2014 15:43 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 1,593 | $7.58 | $12,074.94 |
DisclosureSEC source: 0000904454-14-000809 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,342,094 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $7.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 16, 2014 Filed Dec 18, 2014 15:43 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 6,507 | $7.63 | $49,648.41 |
DisclosureSEC source: 0000904454-14-000809 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,343,687 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.60 to $7.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 12, 2014 Filed Dec 16, 2014 01:48 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 3,645 | $7.51 | $27,373.95 |
DisclosureSEC source: 0000904454-14-000805 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,350,194 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 11, 2014 Filed Dec 16, 2014 01:48 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 1,355 | $7.50 | $10,162.50 |
DisclosureSEC source: 0000904454-14-000805 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,353,839 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 10, 2014 Filed Dec 11, 2014 02:13 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 1,300 | $7.70 | $10,010.00 |
DisclosureSEC source: 0000904454-14-000793 · edgar.xml · nonDerivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,355,194 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.70 to $7.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 09, 2014 Filed Dec 11, 2014 02:13 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 5,000 | $7.73 | $38,650.00 |
DisclosureSEC source: 0000904454-14-000793 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,356,494 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.70 to $7.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 08, 2014 Filed Dec 11, 2014 02:13 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 2,000 | $7.69 | $15,380.00 |
DisclosureSEC source: 0000904454-14-000793 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,361,494 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.60 to $7.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 05, 2014 Filed Dec 5, 2014 23:57 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 4,200 | $7.78 | $32,676.00 |
DisclosureSEC source: 0000904454-14-000787 · edgar.xml · nonDerivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,363,494 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 04, 2014 Filed Dec 5, 2014 23:57 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 10,073 | $7.76 | $78,166.48 |
DisclosureSEC source: 0000904454-14-000787 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,367,694 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 03, 2014 Filed Dec 5, 2014 23:57 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 1,627 | $7.75 | $12,609.25 |
DisclosureSEC source: 0000904454-14-000787 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,377,767 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| December 01, 2014 Filed Dec 3, 2014 19:24 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 1,200 | $7.54 | $9,048.00 |
DisclosureSEC source: 0000904454-14-000781 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,379,394 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.49 to $7.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 26, 2014 Filed Nov 26, 2014 21:18 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 500 | $7.60 | $3,800.00 |
DisclosureSEC source: 0000904454-14-000779 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,380,594 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 21:18 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 1,500 | $7.80 | $11,700.00 |
DisclosureSEC source: 0000904454-14-000779 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,381,094 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.70 to $7.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 24, 2014 Filed Nov 24, 2014 22:45 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 4,000 | $8.02 | $32,080.00 |
DisclosureSEC source: 0000904454-14-000769 · edgar.xml · nonDerivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,382,594 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 21, 2014 Filed Nov 24, 2014 22:45 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 2,400 | $8.25 | $19,800.00 |
DisclosureSEC source: 0000904454-14-000769 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,386,594 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 20, 2014 Filed Nov 24, 2014 22:45 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 3,100 | $8.21 | $25,451.00 |
DisclosureSEC source: 0000904454-14-000769 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,388,994 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 12, 2014 Filed Nov 12, 2014 20:06 UTC | NEVRO CORP NVRO · Entity 12422 | ConversionSeries C Convertible Preferred Stock · Derivative | 246,827 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-14-000731 · edgar.xml · derivative · entry 4 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 246,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock. F2 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock. F2 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 12, 2014 Filed Nov 12, 2014 20:06 UTC | NEVRO CORP NVRO · Entity 12422 | ConversionSeries B Convertible Preferred Stock · Derivative | 2,790,178 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-14-000731 · edgar.xml · derivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 2,790,178 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock. F2 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock. F2 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 12, 2014 Filed Nov 12, 2014 20:06 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 40,000 | $18.00 | $720,000.00 |
DisclosureSEC source: 0000904454-14-000731 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 3,077,005 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| November 12, 2014 Filed Nov 12, 2014 20:06 UTC | NEVRO CORP NVRO · Entity 12422 | ConversionCommon Stock | 3,037,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-14-000731 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 3,037,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Immediately prior to the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 01, 2014 Filed May 5, 2014 18:19 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionSeries B Preferred Stock Warrant (Right to Buy) · Derivative | 36,345 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0000904454-14-000410 · edgar.xml · derivative · entry 11 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 36,345 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3 · derivative.exercise_date: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.underlying: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3 · derivative.underlying: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 01, 2014 Filed May 5, 2014 18:19 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionSeries B Preferred Stock Warrant (Right to Buy) · Derivative | 36,345 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0000904454-14-000410 · edgar.xml · derivative · entry 10 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 36,345 shares Expires 2017-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3 · derivative.exercise_date: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.underlying: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3 · derivative.underlying: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 01, 2014 Filed May 5, 2014 18:19 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | ConversionNon-Voting Series B Preferred Stock · Derivative | 133,827 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-14-000410 · edgar.xml · derivative · entry 9 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 133,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.exercise_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.expiration_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 01, 2014 Filed May 5, 2014 18:19 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | ConversionSeries B Preferred Stock · Derivative | 427,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-14-000410 · edgar.xml · derivative · entry 8 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 427,591 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.exercise_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.expiration_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 01, 2014 Filed May 5, 2014 18:19 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | ConversionNon-Voting Series A Preferred Stock · Derivative | 104,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-14-000410 · edgar.xml · derivative · entry 7 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 247,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.exercise_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.expiration_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 01, 2014 Filed May 5, 2014 18:19 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | ConversionSeries A Preferred Stock · Derivative | 385,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-14-000410 · edgar.xml · derivative · entry 6 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 915,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.exercise_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F2 · derivative.expiration_date: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 01, 2014 Filed May 5, 2014 18:19 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Tax withholdingCommon Stock | 23,438 | $8.00 | $187,504.00 |
DisclosureSEC source: 0000904454-14-000410 · edgar.xml · nonDerivative · entry 5 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Development Corporation Disclosed balance after: 1,750,292 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.